• CTLT
• NVO

EU antitrust regulators to rule on Novo's Catalent buy by Dec. 6

EU regulators will decide by Dec. 6 on Novo Holdings' acquisition of Catalent amid concerns over competition in the weight-loss drug market.

• AMGN
• AZN
• CTLT
• NVO
• PFE
• RHHBY

Roche comes out against allowing takeover of drug manufacturer Catalent

Roche's CEO urged authorities to block Novo Nordisk's acquisition of Catalent, citing potential competition issues in the weight-loss drug market, raising concerns for smaller competitors.

• CTLT
• NVO

Citigroup promotes three bankers in healthcare M&A push

Citigroup promotes Sumit Khedekar, Nishant Jadav, and Michael Guarino to enhance its healthcare investment banking efforts as part of its growth strategy.

• CTLT
• NVO

Catalent CEO to remain in charge of contract drugmaker after Novo Holdings' buyout

Catalent's CEO will remain post-acquisition by Novo Holdings, despite concerns from U.S. consumer groups about potential competition threats in weight-loss and gene therapies.

• CTLT
• NVO

Consumer groups ask FTC to block Novo Holdings-Catalent deal

Consumer groups and unions oppose Novo Holdings' acquisition of Catalent, fearing reduced competition in weight loss and gene therapies, prompting a request for FTC review.

• CTLT
• LLY
• NVO

US Senator Warren calls for scrutiny of Novo Holdings' Catalent deal

Senator Elizabeth Warren urges antitrust review of Novo Nordisk's $16.5 billion acquisition of Catalent, citing concerns over potential anti-competitive advantages in the obesity drug market.

• CTLT

Catalent delays filing of annual report

Catalent delays annual report filing, awaits $16.5 billion takeover by Novo Holdings, surpasses Q4 revenue estimates driven by biologics segment.

• CTLT

Catalent posts strong Q4 results, revenue up 23% YoY